Acute hospital occupancy fell to 32.5% under level 5 of the lockdown
The Cellectra 2000 device is under the spotlight, not the actual vaccine or its positive results, yet Inovio shares dropped 35% in early trade
The 215 trial sites around the world include SA and the pharmaceutical firm hopes to know if the vaccine works by late 2020 or early 2021
Grail, whose list of high-profile investors includes Bill Gates and Jeff Bezos, is developing a blood test that aims to detect multiple cancers
Group profit rose about a fifth in the year to end-June, with the company’s pharmacy delivery businesses faring well amid Covid-19
Business Day TV spoke to Aspen CEO Stephan Saad about the group’s full-year results
Emerging markets targeted for growth after disposals slash pharmaceutical giant’s debt
The drugs maker slashed its debt by more than a third over an 18-month period
The acquisition of the licensed cultivation operation in the Eastern Cape comes as the group seeks to grow its presence in the cannabis market
The proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Revenue in April was 40% lower than the previous year while it had increased on a monthly basis
Among the winners during the Covid-19 pandemic, the company cuts debt to within its target range and delivers strong operational cash flow
The company says the weak rand is squeezing its margins
The group’s revenue in the year to end-June improved, but faced pandemic-related costs
The deal is the latest sign that drug firms are seeking ways to bulk up even as the coronavirus pandemic upends other businesses
The FDA is concerned about the benefit and risk profile of the treatment, filgotinib, and has asked for more data before completing its review
Principia shares climb 11% after the French drugmaker announces the all-cash offer that will see it take full control
Protective value of a healthy lifestyle confirms Vitality model, says deputy CEO Gareth Friedlander
Revolt by investors puts an end to one of the biggest deals in the health sector in 2020
Bausch + Lomb, bought in 2013, is a solid source of revenue, with Bausch US shares rising 28% after the news
